Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

The Maine Center for Disease Control has identified two more positive HIV cases in Penobscot County, bringing the total cases ...

In an interview with The News & Observer, Dr. Barton Haynes talks future of HIV vaccine development after HHS canceled the ...

The UNAIDS annual report warns that Trump-era HIV funding cuts could lead to 6 million more infections and 4 million deaths ...

During his 36-year career at Cancer Center, Michael Emerman, PhD, made fundamental discoveries about HIV, the retrovirus that ...

Abdallah Ochoggia, the advocacy and communications specialist at AIC, told this newspaper that the centre, in partnership with Centres for Disease Control (CDC), has established 112 service delivery ...

But HIV experts had failed to overcome a key problem ... Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more. In a world where healthcare ...

The N-heptad repeat (NHR) of the HIV-1 gp41 prehairpin intermediate (PHI) is an attractive potential vaccine target with high sequence conservation across diverse strains. However, despite the potency ...

Does a blended learning implementation package enhance HIV index case testing in Malawi? A protocol for a cluster randomised controlled trial ...

Sanchez estimates that since the program was launched in 2023, it has led to nearly 7,000 people learning they were living with HIV.The CDC has also said on its website that it cannot continue ...